LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hypokalemia Is Associated With COVID-19 Severity

By LabMedica International staff writers
Posted on 01 Oct 2020
Print article
Image: A low level of potassium (K+), known as  hypokalemia, in the blood serum in COVID-19 patients is associated with disease severity and the need for invasive mechanical ventilation (Photo courtesy of Remedy Health Media).
Image: A low level of potassium (K+), known as hypokalemia, in the blood serum in COVID-19 patients is associated with disease severity and the need for invasive mechanical ventilation (Photo courtesy of Remedy Health Media).
Early studies reported various electrolyte abnormalities at admission in patients who later presented the severe form of coronavirus disease 2019 (COVID-19). Electrolyte imbalance may not only affect patient care, but could provide insights into the COVID-19 pathophysiology.

Hypokalemia is a low level of potassium (K+) in the blood serum. Mild low potassium does not typically cause symptoms. Symptoms may include feeling tired, leg cramps, weakness, and constipation. Low potassium also increases the risk of an abnormal heart rhythm, which is often too slow and can cause cardiac arrest.

Medical scientists at the Alicante General University Hospital (Alicante, Spain) carried out a retrospective cohort study of 306 patients with COVID-19 pneumonia hospitalized in an academic center of Spain. The study period was from the March 3, until May 2, 2020. COVID-19 diagnosis required a positive reverse transcriptase–polymerase chain reaction (RT-PCR) test for SARS-CoV-2, mainly in nasopharyngeal aspirates.

Laboratory data, including C-reactive protein, Procalcitonin, Ferritin, Interleukin-6, Lactate dehydrogenase, D-dimers, Troponin T and Brain natriuretic peptide, and treatments used, including diuretics, were obtained from electronic medical records during admission. The team classified the patients into groups according to the nadir of potassium levels (K+) in the first 72 hours of hospital admission: hypokalemia K+ ≤3.5 mmol/L (which includes severe hypokalemia (<3 mmol/L) and mild hypokalemia (3-3.5 mmol/L)) and normokalemia (>3.5 mmol/L).

The team reported that of the 212 patients with normokalemia, 9% required admission to the intensive care unit (ICU), compared with 30.3% of the 76 patients with mild hypokalemia and 33.3% of the 18 patients with severe hypokalemia. Need for invasive mechanical ventilation was 6.2%, 25%, and 33.3%, respectively. After adjusting for confounders, hypokalemia was independently associated with requiring invasive mechanical ventilation during admission (odds ratio = 8.98).

Hypokalemia was not associated with increased mortality, but was associated with longer hospital and ICU stay. Mortality rates were 16.2% in the normokalemia group, 15.8% in the mild hypokalemia group, and 16.7% in the severe hypokalemia group. Median time in the hospital was seven days for patients with normokalemia, 11 days for patients with mild hypokalemia, and 16.5 days for patients with severe hypokalemia. Median length of time in the ICU was 8 days, 11 days, and 15 days, respectively.

The authors concluded that this sensitive biomarker may reflect the progression of COVID-19, it is independently associated with intensive mechanical ventilation requirement after adjusting by confounders, and should be closely monitored to guide timely treatment. The study was published on September 17, 2020 in the International Journal of Infectious Diseases.

Related Links:
Alicante General University Hospital

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.